Dominant inhibition of Fas ligand-mediated apoptosis due to a heterozygous mutation associated with autoimmune lymphoproliferative syndrome (ALPS) Type Ib
about
Revised diagnostic criteria and classification for the autoimmune lymphoproliferative syndrome (ALPS): report from the 2009 NIH International WorkshopHow I treat autoimmune lymphoproliferative syndromeUse of rituximab for refractory cytopenias associated with autoimmune lymphoproliferative syndrome (ALPS)FAS haploinsufficiency is a common disease mechanism in the human autoimmune lymphoproliferative syndromeCo-inherited mutations of Fas and caspase-10 in development of the autoimmune lymphoproliferative syndromeCharacterization of calmodulin-Fas death domain interaction: an integrated experimental and computational study.Somatic KRAS mutations associated with a human nonmalignant syndrome of autoimmunity and abnormal leukocyte homeostasisThe expanding spectrum of the autoimmune lymphoproliferative syndromesLaboratory evaluation of primary immunodeficienciesHuman genetic approaches to diseases of lymphocyte activation.Association of FAS -670A/G and FASL -843C/T Gene Polymorphisms on Allograft Nephropathy in Pediatric Renal Transplant Patients.Deregulation of Fas ligand expression as a novel cause of autoimmune lymphoproliferative syndrome-like disease.Critical role for BIM in T cell receptor restimulation-induced deathConformation and free energy analyses of the complex of calcium-bound calmodulin and the Fas death domainGenetic defects of apoptosis and primary immunodeficiency.Autoimmune lymphoproliferative syndrome caused by a homozygous null FAS ligand (FASLG) mutation.Bone marrow findings in autoimmune lymphoproliferative syndrome with germline FAS mutationNatural history of autoimmune lymphoproliferative syndrome associated with FAS gene mutationsIdentifying genetic determinants of autoimmunity and immune dysregulation.Restimulation-induced cell death: new medical and research perspectives.Carbon monoxide inhibits T cell activation in target organs during systemic lupus erythematosus.Decreased activation-induced cell death by EBV-transformed B-cells from a patient with autoimmune lymphoproliferative syndrome caused by a novel FASLG mutation.Trifluoperazine regulation of calmodulin binding to Fas: a computational study.Structural insight for the roles of fas death domain binding to FADD and oligomerization degree of the Fas-FADD complex in the death-inducing signaling complex formation: a computational study.Residual CD95-pathway function in children with autoimmune lymphoproliferative syndrome is independent from clinical state and genotype of CD95 mutation.Cell cycle regulation by FasL and Apo2L/TRAIL in human T-cell blasts. Implications for autoimmune lymphoproliferative syndromes.Autoimmune Lymphoproliferative Syndrome-FAS Patients Have an Abnormal Regulatory T Cell (Treg) Phenotype but Display Normal Natural Treg-Suppressive Function on T Cell Proliferation.
P2860
Q24632569-22016FC3-60CB-4EE7-9FEE-F09EE5D2817CQ24633207-9E6A4F6A-460E-4FC7-BC33-B419FCB40F53Q24643047-21C37542-6359-4863-BBC0-8CF67C5E7AA3Q28235519-4F99EB10-4861-4CAB-A528-AB342E2A2F2BQ30838565-BA33D9DE-0A1B-464D-A727-AC366E33CD6AQ33558240-04CB2353-BC78-4EB1-9F48-0EF3AA07E09AQ34149957-F64B88E7-3D9B-410E-BDE9-629A8E1123F3Q35619447-58BCFA5A-CDDF-45EB-B9DC-2CE2CCC0F52EQ36142583-8A6D13CB-6F10-4D07-952A-34E86577ADBCQ36152005-04925A5C-9906-4EE9-906E-87A9693B6B0CQ36244578-CBAB5794-7443-4186-9140-37B7E2EE9453Q36708937-E6D95D05-13BB-45F7-99CE-1304B3BDB6D6Q36862396-F6024C0D-AEF6-4FAA-A323-55EC84E8FF22Q37008175-FDB209EC-C02F-4B53-BEF2-A50EE99627B1Q37142878-F0F7CB7A-8D88-4224-88C6-1AA8B14FB654Q37298573-D946A9C0-1C4B-4F44-9EAD-32F8F8B207A3Q37618832-39E477C6-24AC-4E5D-BAB2-15A79B342FBAQ37670054-94B16865-419F-4823-A730-B5A0E2304B80Q38598383-DB3399A8-61CA-442D-8E4A-4288BA54189CQ39277444-C38778F3-D975-4E72-8147-6B08135F35E7Q40815460-BA5112BB-35AE-4C06-B3A1-30EB12BAA189Q41428240-D6FA0714-B56B-41A0-81F0-F7EC6E40F727Q41850711-43F24780-52A0-465F-AA65-0B296AEBE590Q43014937-2ED35945-306F-400F-970A-1A763DE54F72Q53316605-BCCA4605-FF43-461E-8FD5-525152CD4101Q53477098-89DBFC7B-7865-44EB-B264-802C42C0F3C4Q55297581-03CCCC57-F79F-49E9-958D-0F5E7DBD8050
P2860
Dominant inhibition of Fas ligand-mediated apoptosis due to a heterozygous mutation associated with autoimmune lymphoproliferative syndrome (ALPS) Type Ib
description
2007 nî lūn-bûn
@nan
2007 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Dominant inhibition of Fas lig ...... rative syndrome (ALPS) Type Ib
@ast
Dominant inhibition of Fas lig ...... rative syndrome (ALPS) Type Ib
@en
Dominant inhibition of Fas lig ...... e lymphoproliferative syndrome
@nl
type
label
Dominant inhibition of Fas lig ...... rative syndrome (ALPS) Type Ib
@ast
Dominant inhibition of Fas lig ...... rative syndrome (ALPS) Type Ib
@en
Dominant inhibition of Fas lig ...... e lymphoproliferative syndrome
@nl
prefLabel
Dominant inhibition of Fas lig ...... rative syndrome (ALPS) Type Ib
@ast
Dominant inhibition of Fas lig ...... rative syndrome (ALPS) Type Ib
@en
Dominant inhibition of Fas lig ...... e lymphoproliferative syndrome
@nl
P2093
P2860
P356
P1433
P1476
Dominant inhibition of Fas lig ...... rative syndrome (ALPS) Type Ib
@en
P2093
Christopher Makris
George Pan
Janet K Dale
Jay M McDonald
Jennifer M Puck
Lilia L Bi
Lixin Zheng
Michael J Lenardo
Richard M Siegel
Stephen E Straus
P2860
P2888
P356
10.1186/1471-2350-8-41
P577
2007-07-02T00:00:00Z
P5875
P6179
1038296168